Equities
Health CareMedical Equipment and Services
  • Price (USD)25.47
  • Today's Change0.39 / 1.56%
  • Shares traded3.75m
  • 1 Year change+22.75%
  • Beta1.3643
Data delayed at least 15 minutes, as of Mar 18 2024 20:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Avantor, Inc. is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education and government, and advanced technologies & applied materials industries. Its products include materials and consumables, equipment and instrumentation, and services and specialty procurement. Materials and consumables include chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits and education and microbiology and clinical trial kits. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, freezers, biological safety cabinets and critical environment supplies. Services and specialty procurement include onsite lab and production, clinical, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.

  • Revenue in USD (TTM)6.97bn
  • Net income in USD321.10m
  • Incorporated2016
  • Employees14.50k
  • Location
    Avantor IncBuilding One100 W Matsonford Rd Ste 200RADNOR 19087United StatesUSA
  • Phone+1 (610) 386-1700
  • Fax+1 (302) 636-5454
  • Websitehttps://www.avantorsciences.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Badger Meter Inc703.59m92.60m4.52bn2.14k48.948.7437.416.423.143.1423.8917.601.073.128.79328,781.3014.0312.2617.1814.6039.2939.3813.1612.062.19--0.0036.3624.4010.1639.2527.226.7912.07
Vontier Corp3.10bn376.90m6.65bn8.00k17.877.4813.242.152.422.4219.845.770.71675.186.12386,900.008.7310.8011.1814.0446.2444.6212.1813.361.085.800.71942.24-2.803.03-6.08-0.50187.23--
Cognex Corp837.55m113.23m6.99bn2.99k62.414.6451.738.340.65250.65254.838.770.42131.666.86279,928.805.7010.636.2311.5671.7972.9713.5222.383.40--0.0057.03-16.750.7624-47.46-13.24-9.069.03
MKS Instruments Inc3.62bn-1.84bn8.13bn10.00k--3.28--2.24-27.56-27.5654.1736.950.35132.015.19362,100.00-17.86-1.60-19.57-1.7545.3544.95-50.84-3.252.011.160.6596--2.1111.78-652.85--6.692.44
Bio Rad Laboratories Inc2.67bn-637.32m9.50bn8.03k--1.09--3.56-21.49-21.4991.24306.510.20711.655.43332,660.30-4.949.08-5.169.6053.5655.55-23.8641.974.340.30950.12070.00-4.673.1382.43--3.83--
Bruker Corp2.96bn427.20m12.68bn9.71k31.689.7123.424.282.912.9120.149.490.75421.646.15305,398.2010.858.3814.9911.4051.1749.8514.3911.390.994829.030.47569.8117.149.3644.0318.9116.794.56
Revvity Inc2.75bn179.50m12.96bn11.50k72.811.6421.204.711.445.5022.0363.790.19862.914.42239,180.101.304.761.455.3955.9857.196.5315.341.774.070.33136.52-16.95-0.1982-64.99-5.28-2.690.00
Avantor Inc6.97bn321.10m17.01bn14.50k53.013.2323.522.440.47310.473110.287.760.52715.295.88480,496.602.432.972.763.3533.9333.444.615.061.053.190.51320.00-7.263.51-51.52--31.17--
Illumina Inc4.50bn-1.16bn20.30bn10.59k--3.54--4.51-7.34-7.3428.5136.130.40283.056.26425,306.90-10.37-6.20-12.87-7.2860.9566.39-25.75-15.481.29--0.2058---1.756.2173.64---7.91--
Waters Corp2.96bn642.23m20.89bn7.90k32.5418.1525.847.0710.8410.8449.9219.440.74772.464.15374,229.9016.2419.7720.2825.2959.5758.4521.7223.381.579.940.67190.00-0.52294.09-9.261.534.72--
Veralto Corp5.02bn839.00m21.33bn16.00k25.3915.4123.034.253.413.4120.395.61------313,812.50--------57.78--16.71--1.4038.600.6543--3.10---0.7101------
Data as of Mar 18 2024. Currency figures normalised to Avantor Inc's reporting currency: US Dollar USD

Institutional shareholders

47.82%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 202363.83m9.41%
Dodge & Coxas of 31 Dec 202361.20m9.02%
T. Rowe Price Investment Management, Inc.as of 31 Dec 202352.66m7.76%
Boston Partners Global Investors, Inc.as of 31 Dec 202327.94m4.12%
BlackRock Fund Advisorsas of 31 Dec 202325.34m3.74%
Barrow, Hanley, Mewhinney & Strauss LLCas of 31 Dec 202324.36m3.59%
Canada Pension Plan Investment Boardas of 31 Dec 202322.22m3.28%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 202318.44m2.72%
Janus Henderson Investors US LLCas of 31 Dec 202314.61m2.15%
SSgA Funds Management, Inc.as of 31 Dec 202313.77m2.03%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.